XGN

3.6105.00%
MM

Michael Mahler

Chief Scientific Officer

Dr. Michael Mahler is Chief Scientific Officer at Exagen Inc. since June 2025. He has extensive background in immunology and autoimmune research, Dr. Mahler holds a wealth of expertise to Exagen's mission of improving the diagnosis and treatment of autoimmune diseases. During his doctoral research, he worked at the Scripps Research Institute, more specifically in the lab of Prof. Eng Tan and Michael Pollard, pioneers in autoimmune research. At the same time, Dr. Mahler initiated a productive and lasting collaboration with one of his mentors, Dr. Marvin J. Fritzler, a thought leader in the field whose research spans a wide range of topics, including autoimmune disease, the biology of autoantigens and novel diagnostic technologies. Over the course of his distinguished career, Dr. Mahler has held key positions at various diagnostic companies, most recently serving as Senior Vice President of Research Development and Business Development at Werfen. His transformative work has led to the discovery of several novel autoantigens and the development of innovative diagnostic solutions. His scientific contributions have resulted in over 300 peer-reviewed publications and numerous patents, advancing the accurate diagnosis of autoimmune diseases. Dr. Mahler received his Ph.D. from the Institute of Molecular Genetics at the University of Heidelberg, Germany.

Positions